News
-
-
PRESS RELEASE
AB Science reports its revenues for the year 2025 and provides an update on its activities
AB Science presents annual financial results as of 31 December 2025, focusing on operating loss reduction and key clinical developments like Phase 3 of masitinib in ALS and Phase 1 of AB8939 in AML -
-
PRESS RELEASE
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
AB Science announces new publication on medRxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in amyotrophic lateral sclerosis patients -
-
-
-
-
-
PRESS RELEASE
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041, positioning it uniquely and competitively in the treatment landscape
